Brief: Inhibikase Therapeutics Inc Says 201 Trial Met Primary Endpoint Of Safety And Tolerability
29/01/2025 23:25
Jan 29 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS INC - 201 TRIAL MET PRIMARY
ENDPOINT OF
SAFETY AND TOLERABILITY
* INHIBIKASE THERAPEUTICS INC - RISVODETINIB TREATMENT DID
NOT
SHOW IMPROVEMENT IN TOP HIERARCHICAL EFFICACY MEASURE
Source text: ID:n0001193125-25-015648
Further company coverage: IKT.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary